{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:35:02Z","timestamp":1792794902133,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health and Sanitation Scientific Research Project of the Metallurgical Safety and Health Branch of the Chinese Society for Metals","award":["jkws202318"],"award-info":[{"award-number":["jkws202318"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Metabolic-associated fatty liver disease (MASLD) affects over 25% of the global population, progressing from hepatic steatosis to fibrosis. Current therapies show limited efficacy, and gut microbiota dysbiosis via the gut\u2013liver axis highlights fecal microbiota transplantation (FMT) as a novel intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following preferred reporting items for systematic reviews and meta-analyses guidelines, 8 randomized controlled trials were systematically selected from PubMed, Cochrane, Embase, and Web of Science (inception to September 2025). MASLD patients receiving FMT (any protocol) versus standard care were evaluated for alanine aminotransferase (ALT), aspartate aminotransferase (AST), proton density fat fraction, and body mass index (BMI). Risk of bias was assessed using Cochrane ROB 1.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      FMT significantly reduced ALT (mean difference [MD]\u2005=\u2005\u20106.81, 95% confidence interval [\u201010.29, \u22123.33],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0001) and AST (MD\u2005=\u2005\u20107.13, [\u201010.45, \u22123.80],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001) versus standard care. Subgroup analysis revealed greater ALT improvement in patients aged &lt;50 years (MD\u2005=\u2005\u201014.00, [\u201022.79, \u22125.20],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.002). Proton density fat fraction decreased markedly (MD\u2005=\u2005\u20103.50, [\u20105.12, \u22121.87],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001), while BMI showed no significant change (MD\u2005=\u2005\u20100.69, [\u20101.49, 0.11],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.09).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>FMT effectively improves hepatic inflammation and steatosis in MASLD, with age modulating ALT response. Lack of BMI improvement suggests localized liver effects rather than systemic metabolic impact, supporting FMT as a targeted adjunctive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046886","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:01:18Z","timestamp":1767711678000},"page":"e46886","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Meta-analysis of the effectiveness of fecal microbiota transplantation in the treatment of metabolic-associated fatty liver disease: A systematic review based on liver inflammation indicators and fat content"],"prefix":"10.1097","volume":"105","author":[{"given":"Chunyan","family":"He","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Biomolecular, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin Sci (Lond)"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ecl.2023.01.003","article-title":"Lipid disorders and metabolic-associated fatty liver disease.","volume":"52","author":"Anwar","year":"2023","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases.","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/MPG.0000000000003919","article-title":"Updates in metabolic dysfunction-associated fatty liver disease (MAFLD) in children.","volume":"77","author":"Rupasinghe","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ecl.2023.01.001","article-title":"Pathobiology of metabolic-associated fatty liver disease.","volume":"52","author":"Fouda","year":"2023","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/ijms25115640","article-title":"Metabolic dysfunction-associated steatotic liver disease: from pathogenesis to current therapeutic options.","volume":"25","author":"Portincasa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R9-20260218","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression.","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"R10-20260218","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD.","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R11-20260218","doi-asserted-by":"crossref","first-page":"G563","DOI":"10.1152\/ajpgi.00370.2018","article-title":"Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.","volume":"316","author":"Hartmann","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"11240","DOI":"10.12998\/wjcc.v10.i31.11240","article-title":"Intestinal microbiota in the treatment of metabolically associated fatty liver disease.","volume":"10","author":"Wang","year":"2022","journal-title":"World J Clin Cases"},{"key":"R13-20260218","doi-asserted-by":"crossref","first-page":"923599","DOI":"10.3389\/fimmu.2022.923599","article-title":"The role of gut microbiota in some liver diseases: from an immunological perspective.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"906511","DOI":"10.3389\/fnut.2022.906511","article-title":"Effects of dietary nutrients on fatty liver disease associated with metabolic dysfunction (MAFLD): based on the intestinal-hepatic axis.","volume":"9","author":"Yao","year":"2022","journal-title":"Front Nutr"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/nu17111906","article-title":"Dietary strategies to modulate gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"17","author":"Perazza","year":"2025","journal-title":"Nutrients"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/biomedicines13040779","article-title":"Intestinal microbiota modulation by fecal microbiota transplantation in nonalcoholic fatty liver disease.","volume":"13","author":"Hauser","year":"2025","journal-title":"Biomedicines"},{"key":"R17-20260218","first-page":"CD013871","article-title":"Fecal microbiota transplantation for the treatment of recurrent clostridioides difficile (clostridium difficile).","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20260218","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with nafld via gut microbiome alterations.","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab"},{"key":"R19-20260218","doi-asserted-by":"crossref","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"},{"key":"R20-20260218","doi-asserted-by":"crossref","first-page":"2372881","DOI":"10.1080\/19490976.2024.2372881","article-title":"Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the cxcl16\/cxcr6 axis: a potential treatment for metabolic-associated fatty liver disease.","volume":"16","author":"Zhong","year":"2024","journal-title":"Gut Microbes"},{"key":"R21-20260218","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jceh.2022.05.004","article-title":"Pathogenesis of alcohol-associated liver disease.","volume":"12","author":"Osna","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R22-20260218","first-page":"1488","article-title":"Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment.","volume":"13","author":"Hu","year":"2023","journal-title":"Life (Basel)"},{"key":"R23-20260218","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"R24-20260218","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.fertnstert.2011.05.029","article-title":"A meta-analysis of meta-analyses.","volume":"96","author":"Sigman","year":"2011","journal-title":"Fertil Steril"},{"key":"R25-20260218","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis.","volume":"156","author":"Bajaj","year":"2019","journal-title":"Gastroenterology"},{"key":"R26-20260218","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial.","volume":"70","author":"Bajaj","year":"2019","journal-title":"Hepatology"},{"key":"R27-20260218","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial.","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R28-20260218","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in nafld patients: evidence from a randomized clinical trial.","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"R29-20260218","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis.","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R30-20260218","doi-asserted-by":"crossref","first-page":"21309","DOI":"10.18632\/aging.203460","article-title":"Activation of the gut microbiota\u2013kynurenine\u2013liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults.","volume":"13","author":"Sui","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"R31-20260218","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis.","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun"},{"key":"R32-20260218","doi-asserted-by":"crossref","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial.","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R33-20260218","doi-asserted-by":"crossref","first-page":"120413","DOI":"10.1016\/j.cca.2025.120413","article-title":"Biomarkers in liver regeneration.","volume":"576","author":"Akhtam","year":"2025","journal-title":"Clin Chim Acta"},{"key":"R34-20260218","doi-asserted-by":"crossref","first-page":"15125","DOI":"10.1021\/acsnano.3c04449","article-title":"Gut microbiota participates in polystyrene microplastics-induced hepatic injuries by modulating the gut\u2013liver axis.","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"R35-20260218","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1097\/MCG.0000000000001194","article-title":"Risk factors for gastrointestinal symptoms following successful eradication of clostridium difficile by fecal microbiota transplantation (fmt).","volume":"53","author":"Allegretti","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"R36-20260218","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cgh.2019.07.006","article-title":"Effects of fecal microbiota transplantation with oral capsules in obese patients.","volume":"18","author":"Allegretti","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R37-20260218","doi-asserted-by":"crossref","first-page":"e947157","DOI":"10.12659\/MSM.947157","article-title":"Effects of weight loss on insulin resistance and liver health in t2dm and nafld patients.","volume":"31","author":"Yang","year":"2025","journal-title":"Med Sci Monit"},{"key":"R38-20260218","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jceh.2022.01.007","article-title":"Quantitative ultrasound assessment of hepatic steatosis.","volume":"12","author":"Kaliaev","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R39-20260218","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/metabo14070366","article-title":"Nafld\/masld and the gut\u2013liver axis: from pathogenesis to treatment options.","volume":"14","author":"Vallianou","year":"2024","journal-title":"Metabolites"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:51Z","timestamp":1771434171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046886","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}